Volume 7, Number 2—April 2001
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Economic Impact of Antimicrobial Resistance
|Element||Measurementa||Perspective affected directly|
|Develop new antimicrobial agents||Costs associated with drug development - Profit resulting from new drug's use||Drug industry, HCB, patient, society|
|Conduct surveillance||Cost of surveillance for infected and colonized patients (R) - Cost of surveillance for infected and colonized patients (S)||HCB|
|Implement isolation||Costs associated with barrier isolation (R) - Costs associated with barrier isolation (S)||HCW, visitor, patient, HCB|
|Adapt lab procedures||Costs associated with testing (R) - Costs associated with testing (S)||HCB, patient, society|
|Educate about resistance||Costs associated with educational programs (staff, patients) (R) -Costs associated with educational programs (staff, patients) (S)||HCW, patient, visitor, HCB|
|Improve drug administration||Costs for programs to improve drug administration (R) - Costs for programs to improve drug administration (S)||HCW, HCB|
|Improve drug choice||Costs for programs to improve drug choice (R) - Costs for programs to improve drug choice (S)||Prescribers, HCB|
aR = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business; HCW = health-care workers.
Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."